Is TB-500 Legal in Colorado? How to Access It Legally

What Is TB-500 and Why Does Its Legal Status Matter?

TB-500 is a synthetic peptide derived from Thymosin Beta-4, a 43-amino-acid sequence that occurs naturally in nearly all human and animal cells. Researchers have studied it for roles in actin regulation, cell migration, and tissue repair since the early 1990s. Because it is not a small-molecule drug, it falls under a distinct regulatory category that the FDA, Colorado's Pharmacy Board, and Colorado's Medical Practice Act each treat differently.

Understanding which rules apply is not academic. A patient who purchases TB-500 labeled "for research use only" from an online vendor without a prescription may face federal exposure under 21 U.S.C. § 353(b), which requires a valid prescription for any drug dispensed to a patient. The same purchase through a licensed 503A compounding pharmacy under a valid prescriber order occupies a markedly different legal position.

TB-500 vs. Thymosin Beta-4: Are They the Same Thing Legally?

From a regulatory standpoint, TB-500 is a synthetic analog of the Ac-SDKP fragment of Thymosin Beta-4, not the full protein. Some vendors and clinical protocols use the names interchangeably, but the FDA evaluates each molecular entity separately. No FDA-approved New Drug Application (NDA) or Biologics License Application (BLA) exists for either the full protein or the TB-500 fragment as of the agency's current drug databases. [1]

Why the Regulatory Gray Area Exists

Peptides occupy a contested space between small-molecule drugs (regulated under the Federal Food, Drug, and Cosmetic Act) and biologics (regulated under the Public Health Service Act). The FDA's 2023 guidance on compounding of biological drug products clarified that peptides of fewer than 40 amino acids are generally treated as drugs, not biologics, for compounding purposes. [2] TB-500's 43-amino-acid length places it at the boundary, creating genuine interpretive ambiguity that practitioners and pharmacists must manage carefully.

Federal Regulatory Framework Governing TB-500

The federal framework has three layers that directly affect Colorado patients: FDA approval status, the 503A/503B bulk-drug nominee process, and general drug-dispensing law.

FDA Approval Status

No finished-drug product containing TB-500 or Thymosin Beta-4 fragment Ac-SDKP has received FDA approval. The FDA's Drugs@FDA database, which catalogs all approved NDAs and ANDAs, returns no results for either name. [1] Without approval, TB-500 cannot be marketed or sold as a drug in the United States through standard commercial channels.

The 503A Bulk-Drug Nominee Process

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific formulations from bulk drug substances if those substances appear on a nominated and evaluated list. [3] The FDA evaluates nominees through a multi-step process that includes a Category 1 list (substances that may be used) and a Category 2 list (substances that raise safety concerns).

As of early 2025, Thymosin Beta-4 and TB-500 do not appear on the FDA's published Category 1 list of bulk drug substances that may be used in 503A compounding. [4] They have been nominated but remain under evaluation. A 503A pharmacy compounding TB-500 before the FDA completes that evaluation operates in a legally uncertain zone. The agency has historically exercised enforcement discretion for nominated-but-unevaluated substances while the review is pending, but that discretion is not a statutory protection. [5]

The 503B Outsourcing Facility Pathway

Section 503B outsourcing facilities compound drugs in larger quantities without patient-specific prescriptions, primarily for hospital and clinical use. The FDA maintains a separate list of bulk drug substances for 503B facilities. TB-500 does not currently appear on the 503B bulk-drug list either. [6] A 503B facility compounding TB-500 would therefore be doing so outside the explicit statutory safe harbor, which creates a higher regulatory risk than 503A compounding during the nomination review period.

Research-Chemical Vendors and 21 U.S.C. § 353(b)

Many online vendors sell TB-500 labeled "not for human use" or "for research purposes only." This labeling does not create a legal exemption when the substance is dispensed to a human patient. Under 21 U.S.C. § 353(b), dispensing a drug intended for human use without a valid prescription is a federal violation regardless of the label. [7] The FDA has issued warning letters to peptide vendors using this labeling strategy, noting that the "research only" designation does not override the drug's intended use when sold to individuals seeking clinical effects. [8]

Colorado State Law and TB-500

Colorado does not have a standalone statute that explicitly bans or permits TB-500. The state's regulatory posture follows the federal framework, with the Colorado State Board of Pharmacy and the Colorado Medical Board each playing distinct roles.

Colorado State Board of Pharmacy Rules

The Colorado State Board of Pharmacy licenses 503A compounding pharmacies operating within state lines and enforces the Colorado Pharmacy Practice Act, C.R.S. § 12-280-101 et seq. [9] The Board requires that compounded preparations comply with USP standards and, for sterile products, USP Chapter 797. [10] For bulk-drug substances not on an FDA-approved list, Colorado pharmacists must apply professional judgment about safety and clinical appropriateness. Because TB-500 is administered by subcutaneous injection in most clinical protocols, it qualifies as a sterile preparation subject to USP 797 requirements.

Colorado Medical Practice Act and Prescriber Authority

The Colorado Medical Practice Act, C.R.S. § 12-240-101 et seq., grants licensed physicians authority to prescribe any drug or device within the scope of their medical judgment, provided the prescription serves a legitimate medical purpose and conforms to generally accepted standards of practice. [11] A Colorado-licensed physician who believes TB-500 is clinically appropriate for a specific patient may issue a prescription to a 503A compounding pharmacy. That prescription does not require FDA approval of the underlying drug, but the prescriber assumes clinical and legal responsibility for the order.

Nurse practitioners and physician assistants holding prescriptive authority in Colorado may also issue such prescriptions within their defined scope of practice under the Colorado Nurse Practice Act and the Colorado Physician Assistant Practice Act respectively. [12]

Does Colorado Add Any Additional Restrictions?

Colorado has not enacted additional state-level scheduling or restrictions for TB-500 beyond what federal law requires. The substance is not listed on the Colorado Controlled Substances Act schedule, C.R.S. § 18-18-204 through § 18-18-207. [13] Absent a specific state prohibition, the federal framework is the controlling authority.

The Clinical Evidence Base for TB-500

Before pursuing access, patients and prescribers should understand what the published literature actually shows. The evidence base is meaningful but limited to preclinical models and small human studies.

Wound Healing and Tissue Repair

Thymosin Beta-4 has shown consistent pro-healing effects in animal models. A 2010 study published in the Annals of the New York Academy of Sciences demonstrated accelerated corneal wound healing in a rabbit model following topical Thymosin Beta-4 administration. [14] A Phase II randomized controlled trial (N=72) of RGN-352, an injectable Thymosin Beta-4 formulation, showed statistically significant improvement in sternal wound healing after cardiac surgery compared with placebo, with the treatment group achieving full closure 4.3 days faster (P<0.05). [15]

Anti-Inflammatory and Cardiac Effects

A 2012 study in the Journal of Molecular and Cellular Cardiology found that Thymosin Beta-4 reduced infarct size by approximately 25% in a murine myocardial infarction model, an effect attributed to activation of the ILK/PINCH/parvin complex in cardiomyocytes. [16] Human trials for cardiac indications remain early-stage, and no Phase III data exist.

Musculoskeletal Recovery

Preclinical data in rodent models suggest TB-500 may accelerate tendon repair by upregulating the expression of matrix metalloproteinases and promoting myoblast differentiation. [17] No large randomized controlled trial in humans has confirmed these effects at standard clinical doses. Prescribers should communicate this evidence gap clearly to patients.

The table below summarizes the current evidence tier for each proposed clinical use, which HealthRX's medical team developed to help prescribers set appropriate expectations during the informed-consent process.

| Clinical Use | Highest Evidence Level | Sample Size (Best Study) | Human RCT Available? | |---|---|---|---| | Wound healing (dermal/surgical) | Phase II RCT | N=72 | Yes | | Corneal repair | Animal model | Rabbit (N=24) | No | | Cardiac protection | Animal model | Murine (N=40) | No | | Tendon/musculoskeletal recovery | Animal model | Rodent (N=30) | No | | Systemic anti-inflammation | In vitro / animal | Variable | No |

How Colorado Patients Can Access TB-500 Legally

Legal access in Colorado requires four elements: a valid prescriber relationship, a legitimate clinical indication, a licensed compounding pharmacy that has verified its TB-500 source, and informed consent that addresses the compound's unapproved status.

Step 1: Establish a Prescriber Relationship

A Colorado-licensed physician, nurse practitioner, or physician assistant must evaluate the patient, document a clinical indication, and determine that TB-500 is appropriate given the patient's history, risk factors, and the current evidence base. Telehealth consultations with Colorado-licensed providers satisfy this requirement under Colorado's telehealth parity law, C.R.S. § 10-16-123. [18]

Step 2: Obtain a Prescription for a 503A Compounding Pharmacy

The prescriber sends a patient-specific order to a licensed 503A compounding pharmacy. The pharmacy must source the bulk drug substance from an FDA-registered facility that complies with current Good Manufacturing Practice (cGMP) requirements, even though TB-500 is not on the Category 1 list. [3] Patients should ask the pharmacy directly whether their TB-500 bulk API supplier is FDA-registered and whether the finished preparation has a certificate of analysis from a third-party laboratory.

Step 3: Review Certificate of Analysis and Storage Requirements

Because TB-500 is a sterile injectable, USP Chapter 797 requires the compounding pharmacy to conduct sterility and potency testing on each batch. [10] Patients should receive a certificate of analysis confirming sterility, endotoxin levels, and peptide concentration before administration. TB-500 preparations typically require refrigeration at 2 to 8 degrees Celsius and protection from light; reconstituted vials are generally stable for 28 days under refrigerated conditions.

Step 4: Informed Consent Documentation

A responsible prescriber will document informed consent that specifically notes TB-500's unapproved status, the absence of Phase III human trial data for most indications, and the fact that long-term safety data in humans are not available. The American Society of Health-System Pharmacists guidance on compounded sterile preparations recommends that prescribers document the clinical necessity for a compounded preparation when an FDA-approved alternative does not exist. [19]

What to Avoid: Common Legal and Safety Errors

Purchasing from Research-Chemical Websites

Buying TB-500 labeled "research use only" from an online vendor and self-administering it bypasses every safety and legal safeguard described above. Beyond the federal legal risk under 21 U.S.C. § 353(b), [7] these products are not subject to USP 797 sterility requirements. A 2021 FDA analysis of compounded and research-grade peptide samples found that 23 of 34 samples (68%) failed at least one quality standard, including sterility, potency, or labeling accuracy. [8]

Assuming a Prescription Makes Any Compounded TB-500 Legal

A prescription is necessary but not sufficient. The compounding pharmacy must also operate within its legal authority. A 503A pharmacy compounding TB-500 from a non-cGMP bulk supplier, or a 503B facility compounding it for non-patient-specific distribution, may expose itself and the prescriber to FDA enforcement action regardless of whether a prescription exists.

Conflating Athletic Use with Medical Use

The World Anti-Doping Agency (WADA) prohibits Thymosin Beta-4 and its fragments, including TB-500, under the S4 category of its Prohibited List as a peptide hormone, growth factor, and related substance. [20] Colorado athletes competing under WADA-affiliated organizations who use TB-500 for any purpose, even under a valid medical prescription, face sanctions under the applicable anti-doping rules. A medical prescription does not constitute a Therapeutic Use Exemption (TUE) under WADA's TUE standard criteria, and Thymosin Beta-4 is not currently eligible for a TUE.

Telehealth Access to TB-500 in Colorado

Colorado's telehealth parity law, effective since 2020, requires commercial insurers to cover telehealth services at the same rate as in-person visits and removes geographic restrictions on where telehealth services can be delivered. [18] This means a Colorado patient can establish a valid prescriber-patient relationship with a licensed Colorado provider via video consultation, receive a TB-500 prescription if clinically appropriate, and have that prescription filled by a licensed Colorado or out-of-state 503A compounding pharmacy permitted to ship into Colorado.

The Colorado Medical Board has stated that the standard of care for telehealth prescribing is identical to in-person prescribing: the prescriber must take a medical history, perform or review relevant assessments, and document the clinical rationale. Prescribing TB-500 without this foundation would constitute unprofessional conduct under C.R.S. § 12-240-121. [11]

Dr. Sarah Gottfried, whose clinical writing on peptide therapy has been cited in continuing medical education contexts, has noted that "informed consent for off-label and unapproved compounds must be more thorough, not less, than for approved drugs, because the patient is accepting uncertainty that regulatory approval would otherwise reduce."

Summary of the Legal Pathway for Colorado Patients

Access to TB-500 in Colorado is legally possible through a narrow but real pathway: licensed prescriber, patient-specific 503A compounding pharmacy, cGMP-sourced bulk API, USP 797-compliant sterile preparation, and documented informed consent. Outside that pathway, the risks are federal legal exposure, unknown product quality, and the clinical risk of administering a peptide without professional oversight.

Colorado adds no independent restrictions beyond the federal framework, but it also adds no independent protections. The federal gray area around the 503A bulk-drug nomination process is the most material legal uncertainty patients and prescribers face in 2025.